Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection

BACKGROUND: Haemodialysis patients are at risk of developing severe forms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: coronavirus disease 2019 (COVID-19). In March 2020, hydroxychloroquine (HCQ) and azithromycin (AZI) were proposed as potential treatments of COVID-19,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nephrol Dial Transplant
Autors principals: Giaime, Philippe, Guenoun, Maxime, Pedinielli, Nathalie, Narbonne, Hervé, Bergounioux, Jean-Philippe, Solas, Caroline, Guilhaumou, Romain, Sampol, Jérôme, Ollier, Jacques, Sichez, Hélène, Serveaux, Marianne, Brunner, Flora, Bataille, Stanislas
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7499716/
https://ncbi.nlm.nih.gov/pubmed/32844224
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ndt/gfaa191
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars